Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTX029 and ASTX727 in RAS-Mutant MDS and MDS/MPN
NCT06284460Phase 2Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jan 2025
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of beroterkib in myelodysplastic syndrome (MDS), myelodysplastic/myeloproliferative neoplasms (MDS/MPN), chronic myelomonocytic leukemia (CMML), sponsored by University of Texas MD Anderson Cancer Center. Planned start Jan 2025; status: withdrawn.
02
Drugs
beroterkib
03
Conditions
myelodysplastic syndrome (MDS)myelodysplastic/myeloproliferative neoplasms (MDS/MPN)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT06284460.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06284460.